Shots:

• EdiGene is eligible to receive milestones for clinical development along with royalties after its commercialization while Neukio will develop cell therapies in a specific undisclosed indication
• The collaboration will use EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of iPSC and NK cell to develop iPSC-NK immune cell therapies for the treatment of solid tumors
• EdiGene’s genome-editing screening platform provides a genome-wide exploration of genes towards the growth & differentiation of specific cells & helps to advance the establishment of causality b/w genetic variation and therapeutic development

Ref: Businesswire | Image: Businesswire